转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

两篇JCI证实靶向干扰素或可提高抗逆转录病毒药物治疗HIV的疗效

2016-12-14 佚名 生物谷

转录病毒
关注

尽管联合抗逆转录病毒疗法（cART）能够协助HIV-1阳性病人有效地管控他们的感染病情，但是一些病人会经历免疫系统不断地激活，从而能够恶化病情发展。这种长期激活归因于I型干扰素（IFN-I）的持续信号转导，其中IFN-I是结合到IFN受体上来调节免疫系统的蛋白。 本周，两项新的研究证实在HIV-1感染的人源化小鼠模型中，靶向IFN-I信号的抗体能够加强cART的疗效。相关研究结果均于2016年1


尽管联合抗逆转录病毒疗法（cART）能够协助HIV-1阳性病人有效地管控他们的感染病情，但是一些病人会经历免疫系统不断地激活，从而能够恶化病情发展。这种长期激活归因于I型干扰素（IFN-I）的持续信号转导，其中IFN-I是结合到IFN受体上来调节免疫系统的蛋白。

本周，两项新的研究证实在HIV-1感染的人源化小鼠模型中，靶向IFN-I信号的抗体能够加强cART的疗效。相关研究结果均于2016年12月12日在线发表在Journal of Clinical Investigation期刊上，论文标题分别为“Targeting type I interferon–mediated activation restores immune function in chronic HIV infection”和“The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?”。

在美国加州大学洛杉矶分校科学家Scott Kitchen领导的一项研究中，研究人员利用一种阻断人IFN受体2的抗体治疗被HIV-1感染的小鼠。他们观察到T细胞耗竭和病毒载量下降的迹象，这表明慢性免疫激活下降和感染管控得到改善。

在另一项研究中，美国北卡罗来纳大学Lishan Su实验室开发出一种不同的靶向人IFNα/β受体的抗体，并且观察到它也会逆转HIV-1感染的人源化小鼠体内的免疫过度激活。

在这两项研究中，相比于单独接受cART治疗的HIV-1感染的人源化小鼠，与cART治疗协同进行的IFN-I信号阻断会导致更好的治疗结果。这两项研究的结果强烈支持将IFN-I阻断作为cART治疗的一种辅助手段进行进一步评价。

原始出处

Anjie Zhen,1 Valerie Rezek,1 Cindy Youn,1 Brianna Lam,1 Nelson Chang,1 Jonathan Rick,1 Mayra Carrillo,1 Heather Martin,1 Saro Kasparian,1 Philip Syed,1 Nicholas Rice,1 David G. Brooks,2,3 and Scott G. Kitchen1.Targeting type I interferon–mediated activation restores immune function in chronic HIV infection.JCI.2016

Steven G. Deeks,1 Pamela M. Odorizzi,1 and Rafick-Pierre Sekaly2The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?.JCI.2016


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-07-12 ms1292405679162969

    #抗逆转录病毒#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-27 venlin

    #抗逆转录病毒药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-08-30 mjldent

    #转录#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-01-23 xiaogang317

    #逆转录病毒#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-04-16 caobinglei8079

    #JCI#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1688281, encodeId=ce2a168828119, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Wed Jul 12 22:42:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632288, encodeId=5e9c16322889d, content=<a href='/topic/show?id=8d51558114f' target=_blank style='color:#2F92EE;'>#抗逆转录病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55811, encryptionId=8d51558114f, topicName=抗逆转录病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd3921890223, createdName=venlin, createdTime=Mon Mar 27 16:42:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747219, encodeId=731b1e47219d3, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Aug 30 02:42:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053177, encodeId=228320531e7cd, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Jan 23 23:42:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982040, encodeId=81fe198204077, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Apr 16 16:42:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926837, encodeId=7842192683e6b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Mar 24 15:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 hxj0117

    #逆转录#

    0